Effect of escitalopram on hot flash interference: A randomized, controlled trial

Janet Carpenter, Katherine A. Guthrie, Joseph C. Larson, Ellen W. Freeman, Hadine Joffe, Susan D. Reed, Kristine E. Ensrud, Andrea Z. Lacroix

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Objective: To estimate the effect of escitalopram (10-20 mg/d) versus placebo for reducing hot flash interference in daily life and understand correlates and predictors of reductions in hot flash interference, a key measure of quality of life. Design: Multisite, randomized, double-blind, placebo-controlled clinical trial. Setting: MsFLASH clinical sites in Boston, Indianapolis, Oakland, and Philadelphia. Patient(s): A total of 205 midlife women (46% African-American) who met criteria participated. Intervention(s): After baseline, women were randomized to one pill of escitalopram 10 mg/d (n = 104) or placebo (n = 101) with follow-up at 4 and 8 weeks. At week 4, those not achieving 50% fewer hot flashes were increased to two pills daily (20 mg/d or 2 placebo pills). Main Outcome Measure(s): The Hot Flash Related Daily Interference Scale; correlates were variables from hot flash diaries; predictors were baseline demographics, clinical variables, depression, anxiety, sleep quality, and hot flashes. Result(s): Compared to placebo, escitalopram significantly reduced hot flash interference by 6.0 points at week 4 and 3.4 points at week 8 more than placebo. Reductions in hot flash interference correlated with changes in hot flash diary variables. However, baseline variables did not significantly predict reductions in hot flash interference. Conclusion(s): Escitalopram (10-20 mg/d) for 8 weeks improves women's quality of life and this benefit did not vary by demographic, clinical, mood, sleep, or hot flash variables. Clinical Trial Registration Number: NCT00894543.

Original languageEnglish
JournalFertility and Sterility
Volume97
Issue number6
DOIs
StatePublished - Jun 2012

Fingerprint

Hot Flashes
Citalopram
Randomized Controlled Trials
Placebos
Sleep
Quality of Life
Demography
Controlled Clinical Trials
African Americans
Anxiety

Keywords

  • hot flashes
  • Menopause
  • night sweats
  • selective serotonin reuptake inhibitor

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Reproductive Medicine

Cite this

Carpenter, J., Guthrie, K. A., Larson, J. C., Freeman, E. W., Joffe, H., Reed, S. D., ... Lacroix, A. Z. (2012). Effect of escitalopram on hot flash interference: A randomized, controlled trial. Fertility and Sterility, 97(6). https://doi.org/10.1016/j.fertnstert.2012.03.001

Effect of escitalopram on hot flash interference : A randomized, controlled trial. / Carpenter, Janet; Guthrie, Katherine A.; Larson, Joseph C.; Freeman, Ellen W.; Joffe, Hadine; Reed, Susan D.; Ensrud, Kristine E.; Lacroix, Andrea Z.

In: Fertility and Sterility, Vol. 97, No. 6, 06.2012.

Research output: Contribution to journalArticle

Carpenter, J, Guthrie, KA, Larson, JC, Freeman, EW, Joffe, H, Reed, SD, Ensrud, KE & Lacroix, AZ 2012, 'Effect of escitalopram on hot flash interference: A randomized, controlled trial', Fertility and Sterility, vol. 97, no. 6. https://doi.org/10.1016/j.fertnstert.2012.03.001
Carpenter, Janet ; Guthrie, Katherine A. ; Larson, Joseph C. ; Freeman, Ellen W. ; Joffe, Hadine ; Reed, Susan D. ; Ensrud, Kristine E. ; Lacroix, Andrea Z. / Effect of escitalopram on hot flash interference : A randomized, controlled trial. In: Fertility and Sterility. 2012 ; Vol. 97, No. 6.
@article{df7dcfaf53904b2c8eab8b1a2b4b9734,
title = "Effect of escitalopram on hot flash interference: A randomized, controlled trial",
abstract = "Objective: To estimate the effect of escitalopram (10-20 mg/d) versus placebo for reducing hot flash interference in daily life and understand correlates and predictors of reductions in hot flash interference, a key measure of quality of life. Design: Multisite, randomized, double-blind, placebo-controlled clinical trial. Setting: MsFLASH clinical sites in Boston, Indianapolis, Oakland, and Philadelphia. Patient(s): A total of 205 midlife women (46{\%} African-American) who met criteria participated. Intervention(s): After baseline, women were randomized to one pill of escitalopram 10 mg/d (n = 104) or placebo (n = 101) with follow-up at 4 and 8 weeks. At week 4, those not achieving 50{\%} fewer hot flashes were increased to two pills daily (20 mg/d or 2 placebo pills). Main Outcome Measure(s): The Hot Flash Related Daily Interference Scale; correlates were variables from hot flash diaries; predictors were baseline demographics, clinical variables, depression, anxiety, sleep quality, and hot flashes. Result(s): Compared to placebo, escitalopram significantly reduced hot flash interference by 6.0 points at week 4 and 3.4 points at week 8 more than placebo. Reductions in hot flash interference correlated with changes in hot flash diary variables. However, baseline variables did not significantly predict reductions in hot flash interference. Conclusion(s): Escitalopram (10-20 mg/d) for 8 weeks improves women's quality of life and this benefit did not vary by demographic, clinical, mood, sleep, or hot flash variables. Clinical Trial Registration Number: NCT00894543.",
keywords = "hot flashes, Menopause, night sweats, selective serotonin reuptake inhibitor",
author = "Janet Carpenter and Guthrie, {Katherine A.} and Larson, {Joseph C.} and Freeman, {Ellen W.} and Hadine Joffe and Reed, {Susan D.} and Ensrud, {Kristine E.} and Lacroix, {Andrea Z.}",
year = "2012",
month = "6",
doi = "10.1016/j.fertnstert.2012.03.001",
language = "English",
volume = "97",
journal = "Fertility and Sterility",
issn = "0015-0282",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Effect of escitalopram on hot flash interference

T2 - A randomized, controlled trial

AU - Carpenter, Janet

AU - Guthrie, Katherine A.

AU - Larson, Joseph C.

AU - Freeman, Ellen W.

AU - Joffe, Hadine

AU - Reed, Susan D.

AU - Ensrud, Kristine E.

AU - Lacroix, Andrea Z.

PY - 2012/6

Y1 - 2012/6

N2 - Objective: To estimate the effect of escitalopram (10-20 mg/d) versus placebo for reducing hot flash interference in daily life and understand correlates and predictors of reductions in hot flash interference, a key measure of quality of life. Design: Multisite, randomized, double-blind, placebo-controlled clinical trial. Setting: MsFLASH clinical sites in Boston, Indianapolis, Oakland, and Philadelphia. Patient(s): A total of 205 midlife women (46% African-American) who met criteria participated. Intervention(s): After baseline, women were randomized to one pill of escitalopram 10 mg/d (n = 104) or placebo (n = 101) with follow-up at 4 and 8 weeks. At week 4, those not achieving 50% fewer hot flashes were increased to two pills daily (20 mg/d or 2 placebo pills). Main Outcome Measure(s): The Hot Flash Related Daily Interference Scale; correlates were variables from hot flash diaries; predictors were baseline demographics, clinical variables, depression, anxiety, sleep quality, and hot flashes. Result(s): Compared to placebo, escitalopram significantly reduced hot flash interference by 6.0 points at week 4 and 3.4 points at week 8 more than placebo. Reductions in hot flash interference correlated with changes in hot flash diary variables. However, baseline variables did not significantly predict reductions in hot flash interference. Conclusion(s): Escitalopram (10-20 mg/d) for 8 weeks improves women's quality of life and this benefit did not vary by demographic, clinical, mood, sleep, or hot flash variables. Clinical Trial Registration Number: NCT00894543.

AB - Objective: To estimate the effect of escitalopram (10-20 mg/d) versus placebo for reducing hot flash interference in daily life and understand correlates and predictors of reductions in hot flash interference, a key measure of quality of life. Design: Multisite, randomized, double-blind, placebo-controlled clinical trial. Setting: MsFLASH clinical sites in Boston, Indianapolis, Oakland, and Philadelphia. Patient(s): A total of 205 midlife women (46% African-American) who met criteria participated. Intervention(s): After baseline, women were randomized to one pill of escitalopram 10 mg/d (n = 104) or placebo (n = 101) with follow-up at 4 and 8 weeks. At week 4, those not achieving 50% fewer hot flashes were increased to two pills daily (20 mg/d or 2 placebo pills). Main Outcome Measure(s): The Hot Flash Related Daily Interference Scale; correlates were variables from hot flash diaries; predictors were baseline demographics, clinical variables, depression, anxiety, sleep quality, and hot flashes. Result(s): Compared to placebo, escitalopram significantly reduced hot flash interference by 6.0 points at week 4 and 3.4 points at week 8 more than placebo. Reductions in hot flash interference correlated with changes in hot flash diary variables. However, baseline variables did not significantly predict reductions in hot flash interference. Conclusion(s): Escitalopram (10-20 mg/d) for 8 weeks improves women's quality of life and this benefit did not vary by demographic, clinical, mood, sleep, or hot flash variables. Clinical Trial Registration Number: NCT00894543.

KW - hot flashes

KW - Menopause

KW - night sweats

KW - selective serotonin reuptake inhibitor

UR - http://www.scopus.com/inward/record.url?scp=84861580903&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861580903&partnerID=8YFLogxK

U2 - 10.1016/j.fertnstert.2012.03.001

DO - 10.1016/j.fertnstert.2012.03.001

M3 - Article

C2 - 22480818

AN - SCOPUS:84861580903

VL - 97

JO - Fertility and Sterility

JF - Fertility and Sterility

SN - 0015-0282

IS - 6

ER -